ESTRO 2024 - Abstract Book

S136

Invited Speaker

ESTRO 2024

Luca Boldrini

Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy

Abstract:

The integration of Magnetic Resonance Imaging (MRI) with radiotherapy (MRIgRT) has ushered in a new era of precision and efficacy, also in the treatment of pelvic tumors.

A comprehensive presentation on the current clinical applications of MR guided radiotherapy will be delivered in order to discuss the transformative potential of this technology in improving patient outcomes and quality of life.

The audience will appreciate the ability of MRIgRT to provide real-time, high-resolution imaging of the tumor and surrounding organs, enabling clinicians to precisely delineate tumor boundaries and track organ motion during treatment. This level of precision allows for personalized treatment plans tailored to each patient's anatomy and tumor characteristics, minimizing damage to healthy tissues and maximizing tumor control. For gynecological cancers, MR guided radiotherapy offers enhanced target delineation and dose escalation, improving local control rates while reducing toxicity to nearby critical structures such as the bladder and bowel. In rectal cancer, the ability to visualize tumor response during treatment enables adaptive planning, optimizing radiation delivery and potentially increasing the likelihood of complete tumor regression. Similarly, in prostate cancer, MR guided radiotherapy facilitates accurate tumor localization and tracking, reducing the risk of damage to adjacent organs and improving the preservation of urinary and sexual function. By combining advanced imaging with state-of-the-art radiation delivery, MR guided radiotherapy holds immense promise in improving treatment outcomes, minimizing side effects, and ultimately, enhancing the quality of life for patients affected by pelvic malignancies.

3581

Novel unconventional technologies for hypofractionation

Yolanda Prezado

Universidad Santiago de Compostela, CIMUS, Santiago de Compostela, Spain

Abstract:

Hypofractionated radiation therapy (RT) is supported by a large body of clinical evidence across various cancer sites and in both curative and palliative settings. Despite its growing evidence base and its inclusion in treatment guidelines, concerns around toxicity and late effects of hypofractionation are a significant barrier, especially for certain anatomic sites. Novel unconventional techniques, employing distinct temporal and spatial dose delivery methods can overcome that barrier. Some examples are Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) [1], partial tumor irradiation targeting hypoxic segment of bulky tumors (PATHY) [2], spatially fractionated radiation therapy [3], or FLASH radiotherapy [4]. Those techniques have already demonstrated to be safe in hypofractionation schemes including the treatment of bulky tumors in clinical and preclinical contexts. In this lecture, the different techniques will be described and the advantages for hypofractionated RT discussed.